CRP/Albumin Ratio (CAR) Calculator

Clinical calculation support · Verify results before clinical use

Calculate the CRP/Albumin Ratio

Enter laboratory values using the units shown. The result is calculated automatically after submission.

Use CRP in mg/L. If your laboratory reports mg/dL, convert it to mg/L before entering the value.
Use albumin in g/dL. Convert values reported in g/L to g/dL before calculation.

About the CRP/Albumin Ratio

The C-reactive protein/albumin ratio (CAR) is calculated by dividing serum CRP by serum albumin. CRP is an acute-phase reactant that commonly increases with inflammation, while albumin may decrease during inflammation and in several other clinical conditions.

CAR has been investigated as a prognostic marker in different populations, including critically ill patients with sepsis and patients with malignancy. Evidence and proposed thresholds depend on the population, outcome, assay units, and timing of measurement.

Formula

CAR = CRP (mg/L) ÷ serum albumin (g/dL)

Important points

  • Confirm the units before calculation. This calculator expects CRP in mg/L and albumin in g/dL.
  • Do not apply a cutoff from one disease population directly to another without validation.
  • CAR is an adjunctive biomarker and should not be used alone to diagnose a condition or determine treatment.

References

Ranzani OT, Zampieri FG, Forte DN, Azevedo LCP, Park M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One. 2013;8(3):e59321. doi:10.1371/journal.pone.0059321 · PMID: 23555017
Kinoshita A, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(3):803–810. doi:10.1245/s10434-014-4074-5
Clinical disclaimer: This calculator performs arithmetic only. It does not estimate an individual's probability of an outcome and does not replace clinical assessment. Interpret CAR using evidence applicable to the patient's specific clinical setting.